Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isodiol International Inc ISOLF

Isodiol International Inc is a manufacturer and developer of phytoceutical consumer products using pharmaceutical and nutraceutical grade phytochemical compounds. It generates revenue from the sale of nutritional health products derived from hemp. Geographically, it derives a majority of revenue from the United States and also has a presence in Canada. Its product categories include Tinctures; Capsules; Topicals; Vape; Oral Spray; Skincare; and others.


GREY:ISOLF - Post by User

Bullboard Posts
Comment by Power4Playon Nov 28, 2017 7:33pm
280 Views
Post# 27050282

RE:RE:RE:RE:Let’s all reflect

RE:RE:RE:RE:Let’s all reflect Basic DD

 

Isodiol unit ISO has $4.07M (U.S.) revenue in fiscal Q2

 

2017-10-13 06:55 ET - News Release

 

Mr. Marcos Agramont reports

ISODIOL INTERNATIONAL PROVIDES CORPORATE UPDATE

Isodiol International Inc. has released the fiscal 2018 second quarter revenues of its wholly owned subsidiary, ISO International LLC: $4.07-million (U.S.) ($5.1-million) compared with fiscal 2018 first quarter revenues of $3.92-million (U.S.) ($4.92-million). 

Isodiol International chief executive officer, Marcos Agramont, stated: "Over the last quarter, we have expanded our footprint in Brazil and more recently our operations into Chile. We will continue to push our international expansion strategy by developing the European and Asian markets for our consumer products while working with local health authorities for medical approval of our flagship product, Isoderm. We had another strong quarter of revenue growth and will continue our commitment to delivering high-quality hemp-derived CBD [cannabidiol] products through innovative delivery methods, which is the core of our success."

Bullboard Posts